Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) - Total Assets
Latest total assets as of September 2025: CN¥4.54 Billion CNY
Based on the latest financial reports, Wanbangde Pharmaceutical Holding Group Co Ltd (002082) holds total assets worth CN¥4.54 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wanbangde Pharmaceutical Holding Group Co Ltd - Total Assets Trend (2003–2024)
This chart illustrates how Wanbangde Pharmaceutical Holding Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wanbangde Pharmaceutical Holding Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wanbangde Pharmaceutical Holding Group Co Ltd's total assets of CN¥4.54 Billion consist of 41.7% current assets and 58.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.7% |
| Accounts Receivable | CN¥1.05 Billion | 24.3% |
| Inventory | CN¥213.86 Million | 4.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥515.15 Million | 11.9% |
| Goodwill | CN¥125.67 Million | 2.9% |
Asset Composition Trend (2003–2024)
This chart illustrates how Wanbangde Pharmaceutical Holding Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wanbangde Pharmaceutical Holding Group Co Ltd's current assets represent 41.7% of total assets in 2024, a decrease from 42.8% in 2003.
- Cash Position: Cash and equivalents constituted 3.7% of total assets in 2024, down from 12.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 24.3% of total assets.
Wanbangde Pharmaceutical Holding Group Co Ltd Competitors by Total Assets
Key competitors of Wanbangde Pharmaceutical Holding Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Wanbangde Pharmaceutical Holding Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Wanbangde Pharmaceutical Holding Group Co Ltd generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Wanbangde Pharmaceutical Holding Group Co Ltd generates $ 1.28 in net profit.
Wanbangde Pharmaceutical Holding Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 1.35 | 1.65 |
| Quick Ratio | 1.26 | 1.12 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥555.22 Million | CN¥ 448.95 Million | CN¥ 1.22 Billion |
Wanbangde Pharmaceutical Holding Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wanbangde Pharmaceutical Holding Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.08 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | CN¥4.33 Billion |
| Market Capitalization | $779.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wanbangde Pharmaceutical Holding Group Co Ltd's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Wanbangde Pharmaceutical Holding Group Co Ltd's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2024)
The table below shows the annual total assets of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.33 Billion | +0.72% |
| 2023-12-31 | CN¥4.30 Billion | +1.91% |
| 2022-12-31 | CN¥4.22 Billion | -3.56% |
| 2021-12-31 | CN¥4.37 Billion | -22.80% |
| 2020-12-31 | CN¥5.66 Billion | +48.99% |
| 2019-12-31 | CN¥3.80 Billion | +33.57% |
| 2018-12-31 | CN¥2.85 Billion | +35.49% |
| 2017-12-31 | CN¥2.10 Billion | +26.63% |
| 2016-12-31 | CN¥1.66 Billion | +2.54% |
| 2015-12-31 | CN¥1.62 Billion | +4.27% |
| 2014-12-31 | CN¥1.55 Billion | +0.13% |
| 2013-12-31 | CN¥1.55 Billion | -1.12% |
| 2012-12-31 | CN¥1.57 Billion | +8.31% |
| 2011-12-31 | CN¥1.45 Billion | +9.85% |
| 2010-12-31 | CN¥1.32 Billion | +17.66% |
| 2009-12-31 | CN¥1.12 Billion | +9.51% |
| 2008-12-31 | CN¥1.02 Billion | +10.15% |
| 2007-12-31 | CN¥927.63 Million | +8.93% |
| 2006-12-31 | CN¥851.57 Million | +28.69% |
| 2005-12-31 | CN¥661.73 Million | +58.82% |
| 2004-12-31 | CN¥416.66 Million | +59.29% |
| 2003-12-31 | CN¥261.57 Million | -- |